Literature DB >> 26508138

Pharmacokinetics of Tramadol and O-Desmethyltramadol Enantiomers Following Administration of Extended-Release Tablets to Elderly and Young Subjects.

Sybil Skinner-Robertson1,2, Caroline Fradette2, Sylvie Bouchard2,3, Mohamad-Samer Mouksassi1,4, France Varin5.   

Abstract

BACKGROUND: Tramadol is frequently used in geriatric patients; however, pharmacokinetic (PK) publications on tramadol and O-desmethyltramadol (ODM) in elderly patients are rare.
OBJECTIVE: Our objective was to characterize the PK of tramadol and ODM, including absorption processes and covariates for tramadol, in elderly and young subjects after single-dose administration of 200-mg extended-release tablets.
METHODS: We conducted a PK study in 15 elderly (aged ≥75 years) subjects with mild renal insufficiency and 20 young (18-40 years) subjects; blood and urine samples were collected for 48 h post-dose. Non-compartmental analysis (NCA) of each tramadol and ODM enantiomer included area under the concentration-time curve (AUC), terminal elimination rate (k el), total body clearance, volume of distribution (V area/ F), and renal clearance (Clr0-48). A one-compartment population model of total tramadol concentration was parameterized with clearance (CL/F), volume of distribution (V/F), and mixed order absorption (first-order and zero-order absorption rate constants with lag times).
RESULTS: NCA demonstrated comparable maximum plasma concentration (C max) and AUC between age groups for tramadol enantiomers, but significant differences in V area/ F (mean 34% higher) and k el (mean 28% lower) in the elderly. PK of ODM were significantly different in the elderly for AUC0-inf (mean 35% higher), Clr0-48 (mean 29% lower), and k el (mean 33% lower). The population analysis identified age as a covariate of V/F (young 305 L; elderly 426 L), with a 50% longer mean elimination half-life in the elderly. No differences in absorption processes were observed.
CONCLUSIONS: Tramadol exposure was similar between the age groups; exposure to ODM was higher in elderly subjects.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26508138     DOI: 10.1007/s40266-015-0315-4

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  36 in total

1.  Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effects of main active metabolites of tramadol, (+)-O-desmethyltramadol and (-)-O-desmethyltramadol, in rats.

Authors:  M Valle; M J Garrido; J M Pavón; R Calvo; I F Trocóniz
Journal:  J Pharmacol Exp Ther       Date:  2000-05       Impact factor: 4.030

2.  A randomized, double-blind, 8-week crossover study of once-daily controlled-release tramadol versus immediate-release tramadol taken as needed for chronic noncancer pain.

Authors:  André D Beaulieu; Paul Peloso; William Bensen; Alexander J Clark; C Peter N Watson; Jacqueline Gardner-Nix; G Thomson; Paula S Piraino; John Eisenhoffer; Zoltan Harsanyi; Andrew C Darke
Journal:  Clin Ther       Date:  2007-01       Impact factor: 3.393

3.  Population pharmacokinetic/pharmacodynamic modelling of the analgesic effects of tramadol in pediatrics.

Authors:  María J Garrido; Walid Habre; Ferdinand Rombout; Iñaki F Trocóniz
Journal:  Pharm Res       Date:  2006-08-09       Impact factor: 4.200

4.  A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.

Authors:  A S Levey; J P Bosch; J B Lewis; T Greene; N Rogers; D Roth
Journal:  Ann Intern Med       Date:  1999-03-16       Impact factor: 25.391

5.  Influence of tramadol on neurotransmitter systems of the rat brain.

Authors:  M C Frink; H H Hennies; W Englberger; M Haurand; B Wilffert
Journal:  Arzneimittelforschung       Date:  1996-11

6.  Utilization of pharmacogenomics and therapeutic drug monitoring for opioid pain management.

Authors:  Paul J Jannetto; Nancy C Bratanow
Journal:  Pharmacogenomics       Date:  2009-07       Impact factor: 2.533

7.  Uptake/efflux transport of tramadol enantiomers and O-desmethyl-tramadol: focus on P-glycoprotein.

Authors:  Mouna Kanaan; Youssef Daali; Pierre Dayer; Jules Desmeules
Journal:  Basic Clin Pharmacol Toxicol       Date:  2009-05-26       Impact factor: 4.080

8.  [Biotransformation of tramadol in man and animal (author's transl)].

Authors:  W Lintz; S Erlaçin; E Frankus; H Uragg
Journal:  Arzneimittelforschung       Date:  1981

Review 9.  Tramadol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute and chronic pain states.

Authors:  C R Lee; D McTavish; E M Sorkin
Journal:  Drugs       Date:  1993-08       Impact factor: 9.546

10.  Extended-release tramadol (tramadol ER) in the treatment of chronic low back pain.

Authors:  Gary J Vorsanger; Jim Xiang; Theophilus J Gana; Maria Luz G Pascual; R Rosanna B Fleming
Journal:  J Opioid Manag       Date:  2008 Mar-Apr
View more
  5 in total

1.  Comment on: Pharmacokinetics of Tramadol and O-Desmethyltramadol Enantiomers Following Administration of Extended-Release Tablets to Elderly and Young Subjects.

Authors:  Karel Allegaert
Journal:  Drugs Aging       Date:  2016-02       Impact factor: 3.923

2.  Population Pharmacokinetic/Pharmacodynamic Modeling of O-Desmethyltramadol in Young and Elderly Healthy Volunteers.

Authors:  Sybil Skinner Robertson; Mohamad Samer Mouksassi; France Varin
Journal:  Drugs Aging       Date:  2019-08       Impact factor: 3.923

Review 3.  What Do We Know about Opioids and the Kidney?

Authors:  Mary Mallappallil; Jacob Sabu; Eli A Friedman; Moro Salifu
Journal:  Int J Mol Sci       Date:  2017-01-22       Impact factor: 5.923

4.  Tapentadol Versus Tramadol: A Narrative and Comparative Review of Their Pharmacological, Efficacy and Safety Profiles in Adult Patients.

Authors:  Lucien Roulet; Victoria Rollason; Jules Desmeules; Valérie Piguet
Journal:  Drugs       Date:  2021-07-01       Impact factor: 9.546

5.  Toxicokinetics of U-47700, tramadol, and their main metabolites in pigs following intravenous administration: is a multiple species allometric scaling approach useful for the extrapolation of toxicokinetic parameters to humans?

Authors:  Frederike Nordmeier; Iryna Sihinevich; Adrian A Doerr; Nadja Walle; Matthias W Laschke; Thorsten Lehr; Michael D Menger; Peter H Schmidt; Markus R Meyer; Nadine Schaefer
Journal:  Arch Toxicol       Date:  2021-10-03       Impact factor: 5.153

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.